Indicated for long term female contraception. Click here for Sayana®-Press (medroxyprogesterone acetate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
See patients annually with a once-every-13-weeks, self-administered LARC.
A highly effective, convenient contraceptive option for women:1-5
Cohort studies evaluating self-administration of DMPA-SC showed that with appropriate training and instruction:2-5
Healthcare professional (HCP)-administered Sayana-Press or Depo-Provera® can require four or more clinic visits a year for women. When women receive 12 months’ supply of Sayana-Press from a single visit, less frequent visits can result in:
Women should be re-evaluated periodically as clinically appropriate and at least every year to determine if Sayana-Press is still the best option for them.1
Self-administered DMPA-SC resulted in the same therapeutic levels as HCP-administered DMPA-SC2
Determining which patients are likely to be successful with self-administration is ultimately down to using your best judgment. Here are a few considerations that may help you select the right women for self-administration:
There are a few contraindications to be aware of with Sayana-Press. It is contra-indicated:
Self-administration should be first performed under the supervision of a HCP following training of the woman in proper injection technique and the schedule of administration.
If considered appropriate by the HCP, subsequent injections may be administered by the woman following suitable instruction on injection technique.
Watch this guide on self-administrating Sayana-Press.
To read the full special warnings and precautions for use for Sayana-Press and see a full list of adverse events, refer to the Summary of Product Characteristics. The benefits of contraceptive options and their risks must be evaluated individually for each woman. If any of the conditions/risk factors mentioned is present, the benefits of Sayana-Press use should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using it. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide on whether Sayana-Press use should be discontinued.
Your patients can set a reminder helping them to remember to take their injection on time.
How to register for the self-administration Sayana-Press Text reminder service:
Txt SELF and the date the injection was given to 83311 in this format DD.MM (e.g. SELF 31.07).
One week before the next injection is due a reminder text will be sent. After each injection, your patient will need to re-register for the service.
What can women expect from Sayana-Press?
For a list of adverse events please refer to the SPC
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021